Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POP-ELA preoperative elacestrant study in premenopausal ER-positive/HER2-negative breast cancer
2024-520051-24-00Phase 2Authorised
- Sponsor
- Gustave Roussy
- Start
- Aug 2025
- Modality
- Small Molecules, Peptides, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of elacestrant and leuprolide in breast cancer (2 arms), sponsored by Gustave Roussy. Primary endpoint: Change from baseline in Ki67. Planned start Aug 2025; status: authorised.
02
Drugs
elacestrantleuprolide
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-520051-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520051-24-00.